TD Private Client Wealth LLC Has $1.96 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• TD Private Client Wealth LLC reduced its stake in Thermo Fisher Scientific by 35.9% during the second quarter, now holding 4,838 shares valued at approximately $1.96 million.
• Several large investors have significantly increased their positions in Thermo Fisher, with GAMMA Investing LLC's stake rising by over 60,000% in the first quarter.
• Thermo Fisher Scientific's most recent earnings report exceeded expectations, with a reported EPS of $5.36 against an estimated $5.22.

TD Private Client Wealth LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,838 shares of the medical research company's stock after selling 2,712 shares during the quarter. TD Private Client Wealth LLC's holdings in Thermo Fisher Scientific were worth $1,962,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TMO. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the period. Nuveen LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. Sarasin & Partners LLP bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $242,991,000. EdgePoint Investment Group Inc. bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. Finally, Cohen Investment Advisors LLC increased its position in Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after buying an additional 331,180 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $459.34 on Friday. The stock's 50-day simple moving average is $475.73 and its 200 day simple moving average is $448.37. The firm has a market capitalization of $173.45 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same period last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.